San Diego-based Cidara Therapeutics and Rutgers University were awarded a $5.5 million grant to research and further develop an immunotherapy platform.
The five-year, $5.5 million grant came from the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
The funding will go toward Cidara’s cloudbreak antibody-drug conjugate platform, which looks to identify agents for the treatment and prevention of life-threatening, multi-drug resistant bacterial infections.
Cidara’s platform positions itself as a new approach for treating infectious disease.
“An agent designed to treat and prevent Gram-negative infections in high-risk populations by engaging the immune system would provide an alternative strategy for addressing a critical public health need,” said Jeffrey Stein, president and CEO of Cidara, in a news release.
Under the grant, initial preclinical development will occur at the Public Health Research Institute of New Jersey Medical School, Rutgers University, located in New Jersey.